TMO vs DHR: side-by-side analysis
Cross-read of TMO (TMO) versus DHR (DHR): TMO looks modestly undervalued at $474 versus a fair-value midpoint of $501, while DHR appears in our peer table at a forward P/E of 18.8x and ROE of 7.1%. Our current rating for TMO is Hold.
Where TMO and DHR sit on fair value
TMO's composite fair-value range is $384–$619 (midpoint $501), versus a current price of $474. DHR is one of TMO's closest sector neighbours and shows up directly in the peer table inside our full report, with a market-cap of $121.1B, P/E of 18.8x, EV/EBITDA of 17.4x, and an operating margin of 22.9%. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between TMO and DHR is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
TMO is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. DHR, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 17.3× forward P/E with a PEG of 2.89 is not the same on TMO as it is on DHR unless they share the same growth profile, capital intensity, and moat half-life.
TMO's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against DHR should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: TMO looks modestly undervalued versus our fair-value midpoint. The full report's peer table compares TMO and DHR directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for TMO is bound by the kill-scenarios list in Section 2; the equivalent for DHR would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether TMO or DHR is the better expression of the same theme.
Bottom line — TMO or DHR?
Our rating for TMO is Hold with a 88/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes DHR. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on TMO, including the explicit peer multiples versus DHR and the rest of the comp set, see the canonical report at /stocks/tmo/analysis. For DHR's standalone report, see /stocks/dhr/analysis.
Frequently asked questions
TMO vs DHR: which is cheaper today?
TMO looks modestly undervalued at $474 versus a fair-value midpoint of $501 (range $384–$619). The peer table inside the full report compares TMO and DHR directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is TMO a better buy than DHR?
Our current rating for TMO is Hold; we do not co-rate DHR on this page — see DHR's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is TMO?
TMO is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. DHR's own archetype is in its own report.
What is TMO's moat score versus DHR?
TMO's moat score is 9/10. The full moat section covers source, durability, and threat timeline; DHR's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full TMO report for the canonical evidence.